Introduction
High-grade cervical intraepithelial neoplasia (CIN) is a precursor to cervical squamous cell carcinoma(1-3). The peak incidence of high-grade CIN is in women under age 25 years but cervical squamous cell carcinoma is rare in this age group (4) (5) (6) (7) . There are data to show that a significant proportion of cases of CIN2 in adolescent and young women (under age 21 years) will spontaneously regress (7) (8) (9) and because the risk of progression to malignancy appears to be low in this age group, excisional or ablative treatment may not be indicated. Young women diagnosed with CIN2 who are likely to comply with follow up may be offered conservative management including observation with colposcopy and cytological evaluation every 4 to 6 months to permit spontaneous regression of CIN2 and to avoid potentially unnecessary and costly treatment (7) (8) (9) (10) (11) (12) . Excisional treatments such as the loop excisional procedure (LEEP) are associated with physical, psychological (13) (14) (15) and obstetric morbidity (16) (17) (18) and may have a negative impact on sexual function (14, 19, 20) .
Guidelines suggest that conservative management for adolescents with CIN2 may be considered in appropriately selected cases, but few studies have addressed this issue in women aged 20 to 25 years (7, 10) . Given the potential for treatment-related complications many practitioners have offered women in this age group who are diagnosed with CIN2 the option of conservative management. The aim of our study was to investigate the rate of spontaneous regression of CIN2 in Western Australian women aged 18 to 24 years to determine whether conservative management for appropriately selected patients in this age group might be a reasonable alternative to immediate treatment.
Material and methods
This study was a retrospective cohort study. Women aged 18 to 24 years, were followed-up from the time of their first CIN2 diagnosis (cervical biopsy test result) until their last cytology/histology record. Ethical approval for this study was granted from the Human Only women aged 18 to 24 years with a histological confirmation of CIN2 were included in this study. Women were excluded if they i) had a past history of a histologically confirmed high-grade intraepithelial lesion that was more severe than a CIN2 or (ii) 12 months of follow-up data (cervical cytology or histology) was unavailable.
The Australian Guidelines recommend that women with a cervical smear test result of HSIL should be referred to a gynaecologist for colposcopic assessment and targeted biopsy 4 .
Ideally women with cervical cytology showing HSIL, or possible HSIL should be assessed within two months of diagnosis. Assessment includes colposcopy +/-cervical biopsy. As such, women were allocated into a group dependent on when CIN2 treatment (excisional or ablative) was performed. To allow for women's attendance for gynaecological assessment and treatment, timeframes were slightly extended to the following:
1. If the woman was treated for CIN2 within 4 months they were allocated to the "immediate treatment" group(4).
2.
If treatment for CIN2 was performed > 4 months women were allocated to the "conservative management" group(4,7).
Outcome measures were disease regression (i.e. negative or low-grade lesions including a low-grade squamous intraepithelial lesion (LSIL) on cytology and/or mild dysplasia (CIN1) or atypia on a subsequent biopsy), disease persistence including HSIL (CIN2, CIN3 or adenocarcinoma-in-situ) and disease progression (cervical cancer). Disease regression, persistence or progression was determined from histology test results where possible.
In the absence of histology, cytological findings were used and a hierarchical system was adopted to report the most severe diagnosis for the patient. In the event that a patient had evidence of regression but at a later follow-up visit cytology or histology confirmed persistence or disease progression, the latter diagnosis was reported.
Statistical analysis
Equality of demographic and clinical characteristics of women on different treatment pathways were tested using χ 2 tests. Time-to-event analyses were performed to investigate factors associated with the rate of regression for women that remained untreated (n=924) for CIN2 by 24 months. The follow-up interval was recorded as the time from the CIN2 diagnosis to disease regression (the event) defined as negative cytology and/or biopsy, LSIL or a low-grade glandular abnormality. Participant follow-up was censored at treatment of CIN2 disease, progression or at the time of the last available cervical cytology and/or biopsy result. If women underwent treatment but had a negative treatment specimen on histopathology they were recorded as having had disease regression. Covariates included in the time-to-event analysis were age, socio-economic status and an index of accessibility to services.
Statistical significance was determined as a p-value < 0.05. Stata Version13.0 (Stata Corporation, College Station, USA) was used for data manipulation and statistical analysis.
Results
During the ten-year study period, 2,692 women were aged 18 to 24 years at the time of their initial CIN2 diagnosis. Two hundred seventy five women were excluded from the study because 12 months of follow-up data (cytology or histology test results) were unavailable (n=275). For the remaining 2,417 women, demographic information and comparative statistics are reported in Table 1 There were 462 women with a histological diagnosis of CIN2 (on cervical punch biopsy) who did not undergo treatment during the follow up period. The majority (n=404) of these women had repeat cervical cytology within 6 months of initial diagnosis. A small proportion (3.7%) subsequently had cervical cytology reported as CIN3 during the study follow-up period but are yet to have histological confirmation (outside the study period). In 445 women follow-up cervical cytology and histology indicated disease regression. The median follow-up time for women without a treatment record was 1.8 years.
Multivariate time to event analysis was performed for those women (n=924) conservatively managed to obtain the disease regression hazard rate ratio. Women were censored after treatment and/or when disease progression was confirmed. There was no statistically significant association identified between the rate of regression and patient age A Kaplan Meir graph ( Figure 1 ) was constructed (censoring women at the time of treatment and/or if disease progression was identified) which highlights that the majority of women within the "conservative management" group regressed within 12 months following their initial CIN2 diagnosis. The two-year CIN2 regression rate was estimated to be 59.5%
(95% CI 0.5 -0.6) in this cohort of young women.
Discussion
The aim of our study was to investigate disease outcomes of conservatively managed women aged 18 to 24 years with biopsy confirmed CIN2. Outcome variables measured included rates of CIN2 regression, persistence or progression to higher grade dysplasia or invasive cervical cancer or other associated gynaecological disease. Linked administrative health data sets were used to ascertain these outcomes in a large cohort of Western Australian women with biopsy confirmed CIN2. From Kaplan Meir analysis it was estimated that 59.5%
of conservatively managed women with CIN2 regressed by 24 months post diagnosis. There were no cases of invasive cervical cancer amongst the conservatively managed cohort.
Furthermore, 331 (13.7%) patients who received immediate or conservative treatment were found to have either normal or low-grade histology in the excisional specimen.
The management of young women (<25 years) with screen-detected cervical abnormalities is contentious as there is no clear evidence to suggest that screening patients under this age prevents cervical cancer (26) (27) (28) . Thus, previous management strategies are no longer universally accepted for young women with biopsy confirmed CIN2(7,9,11). As such, specialist obstetrician/gynaecologists are encouraged to consider offering conservative management to appropriately selected patients, in order to minimise potential treatment related physical, psychological and obstetric morbidity(7).
To date there is evidence demonstrating CIN2 regression in up to 65% of adolescents and young women (<21 years) over an 18-month period and hence conservative management in this population may be warranted (8, 9, 12) . However, only a small number of studies have investigated the rate of CIN2 regression in women up to 25 years of age, most of which are limited due to their small sample size(7). To our knowledge this is the largest populationbased study to have analysed outcomes by patient age and socio-economic status in women aged 18 to 24 years with biopsy confirmed CIN2. This study contributes to, and reinforces the health outcomes highlighted in previous research(7).
In any study of natural history outcomes in untreated CIN2 an important consideration is misclassification of histopathological diagnosis. The reporting of cervical specimens (cytology and biopsy specimens) possesses a degree of subjectivity and CIN2 may be overdiagnosed in some cases. In Australia, laboratories that report cervical abnormalities are Furthermore, our inclusion criteria to this study required biopsy confirmation of a CIN2 lesion. As such, the lesion may not have 'truly' spontaneously cleared as the biopsy may have accelerated the clearance of the disease (i.e. specifically if it was a very small lesion). It is important to note that CIN2 is the least reproducible of all cervical diagnoses, and it is possible that the 'regression' of CIN2 is dependent on the individual pathologist reporting the lesion (30) (31) (32) (33) . The potential inclusion of 'equivocal' CIN2 lesions could also be expected to increase the overall regression rate and consequently, regression may have been over-reported (30, 31) . These limitations emphasize the need for further prospective studies that report treatment determinants and also report reproducible biomarkers (i.e. p16 staining of CIN2 specimens).
In recommending conservative management following the diagnosis of CIN2 patient safety is paramount. In our study amongst those patients who were treated conservatively, none progressed to invasive cervical cancer, although eight cases of adenocarcinoma in situ (ACIS) were identified (0.9%). Amongst those women who received immediate treatment, there were cases of ACIS (n = 11), squamous cell carcinoma (n = < 5), and adenocarcinoma (n = < 5) that had not been identified initially. These cases highlight the need for cautious implementation of a conservative management protocol in young women diagnosed with CIN2, and the need for careful selection of patients, regular follow-up evaluation, maintenance of clinical standards and appropriate follow-up systems.
Potential sequelae of conization and LEEP include not only the physical and psychological, but also adverse obstetric outcomes such as second trimester miscarriage and early pre-term delivery (34, 35, 36, 37) . Epidemiological data suggest that these risks correlate with depth of excision and are more frequent following conization (34, 37) . Based on the 59.5% regression rate reported in this study conservative treatment of CIN2 may be an appropriate option, in the form of regular surveillance, for patients less than 25 years of age.
These women should remain under specialist care which routinely provides colposcopy, cytological testing and quality assurance throughout the patient's clinical management, for at least 24 months prior to invasive treatment. Number at risk
